ID | 1085 |
Name of the vaccine | Actacel |
Microbe | Bacteria |
Disease name | Tetanus (Lock Jaw) |
Name of bacteria | Clostridium tetani |
Type of vaccine | Subunit |
Nucleic acid content | DNA |
Age | 2 months to 6 years |
Description of the vaccine | Act-HIB reconstituted with TRIPACEL is Diphtheria, tetanus, acellular pertussis, Haemophilus influenzae type b conjugate vaccine. |
Name of the manufacturer | Sanofi Pasteur Ltd |
Name of the manufacturing country | Canada |
Year of manufacture | 2001 |
Clinical Phase status | Approved |
Bacterial strain | An obligate anaerobic bacillus, which is gram positive. |
Efficacy | NA |
Vaccine formulation | White to off-white suspension |
Dosage | Three dose immunization series, interval of 2 months, followed by a fourth dose. |
Mechanism of action | NA |
Route of administration | Intramuscular |
Indications | Immunization against diphtheria, tetanus and pertussis and invasive Haemophilus influenzae type b infections. |
Export | Marketing Authorisation Holder: Sanofi Pasteur Ltd, Bangkok, Thailand |
Approval | Thailand FDA |
Adjuvant | Aluminium phosphate |
Repurposing | For diphtheria, Hib and acellular pertussis. |
Side effects of vaccine | Injection site tenderness, swelling, redness, fever, fussiness, irritability, less active, eating less, crying, diarrhoea. |
Post vaccination | NA |
Dose type | Combination doses |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NA |
Reference | http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=761 |
Other name | NA |
Additional Links | https://www.fda.moph.go.th/sites/drug/Summary/2C_25_44_N.pdf
|